Valuation: Insmed Incorporated

Capitalization 22.52B 19.21B 17.61B 16.67B 30.9B 2,155B 31.19B 210B 81.7B 1,022B 84.5B 82.72B 3,552B P/E ratio 2026 *
-38.6x
P/E ratio 2027 * 146x
Enterprise value 21.92B 18.69B 17.14B 16.23B 30.07B 2,098B 30.36B 204B 79.51B 995B 82.24B 80.5B 3,457B EV / Sales 2026 *
12.9x
EV / Sales 2027 * 7.79x
Free-Float
99.46%
Yield 2026 *
-
Yield 2027 * -
1 day+11.66%
1 week-17.15%
Current month-14.91%
1 month-25.07%
3 months-21.85%
6 months-40.11%
Current year-33.35%
1 week 98.9
Extreme 98.9
142.58
1 month 98.9
Extreme 98.9
156.64
Current year 98.9
Extreme 98.9
186.19
1 year 64.84
Extreme 64.845
212.75
3 years 18.08
Extreme 18.085
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 9.02
Extreme 9.02
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 71 2013-10-29
Change 5d. change 1-year change 3-years change Capi.($)
+11.66%-17.15%+78.24%+512.14% 22.52B
+1.01%+2.02%+40.77%+89.57% 50.65B
+1.48%+0.71%+86.81%+62.75% 48.58B
+0.34%-5.73%+0.96%-8.70% 23.6B
+1.94%-2.49%+45.89%-27.68% 17.47B
+3.22%+0.29%+29.83%-40.31% 16.06B
-0.99%+1.72%+54.12%+196.47% 15.45B
+1.55%+11.60%-20.91%+884.42% 14.48B
+2.58%-0.04%+43.55% - 13.38B
-0.50%+11.98%+36.74%+155.61% 12.49B
Average +2.23%-1.42%+39.60%+202.70% 23.47B
Weighted average by Cap. +2.19%-1.82%+46.54%+160.73%

Financials

2026 *2027 *
Net sales 1.7B 1.45B 1.33B 1.26B 2.33B 163B 2.35B 15.83B 6.16B 77.14B 6.38B 6.24B 268B 2.76B 2.35B 2.16B 2.04B 3.79B 264B 3.82B 25.72B 10.01B 125B 10.36B 10.14B 435B
Net income -572M -488M -447M -423M -785M -54.73B -792M -5.33B -2.07B -25.96B -2.15B -2.1B -90.21B 99.75M 85.08M 78.03M 73.86M 137M 9.55B 138M 929M 362M 4.53B 374M 366M 15.74B
Net Debt -603M -514M -471M -446M -827M -57.69B -835M -5.62B -2.19B -27.36B -2.26B -2.21B -95.07B -1.03B -876M -803M -760M -1.41B -98.28B -1.42B -9.57B -3.73B -46.62B -3.85B -3.77B -162B
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
26-05-12 116.00 $ +11.66% 8,244,820
26-05-11 103.89 $ +2.51% 7,898,445
26-05-08 101.35 $ -3.48% 8,588,262
26-05-07 105.00 $ -23.41% 13,718,250
26-05-06 137.09 $ -1.69% 2,302,230
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
103.89USD
Average target price
204.75USD
Spread / Average Target
+97.08%

Quarterly revenue - Rate of surprise